Skip to main content
S&P 5007,561.67-0.40%DOW52,347.55+0.10%NASDAQ25,136.27-0.91%BTC$68,258.00-3.68%ETH$1,927.42-4.09%GOLD$3,887.60+0.06%OIL$88.92+0.20%
Smart Investors Daily
SID Premium
TN

NASDAQ · TNXP

Tonix Pharmaceuticals Holding Corp.

Healthcare · Biotechnology

$3.01

Down-$0.23 (-7.10%)

Updated Nov 15, 2026, 1:36 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
172.07M
P/E ratio
-2.71
Dividend yield
0.00%
52-week range
$2.90 – $17.00
Volume
1.94M
Avg. volume
886.98K

Price performance · TNXP

TNXP price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

TNXP closed at $3.01 after 20 trading sessions, down 47.47% for the selected period.

Last close
$3.01
Period change
-47.47%
Period low
$3.01
Period high
$5.78
Daily close
View OHLC price history
TNXP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$3.25$3.25$2.90$3.011.94M
Nov 12, 2026$3.96$3.96$3.21$3.242.45M
Nov 11, 2026$4.16$4.17$3.82$3.873.18M
Nov 10, 2026$4.51$4.60$4.07$4.101.01M
Nov 9, 2026$4.105$5.0087$4.00$4.491.45M
Nov 6, 2026$4.68$4.83$4.63$4.74741.82K
Nov 5, 2026$5.10$5.10$4.55$4.601.21M
Nov 4, 2026$5.28$5.38$5.085$5.11413.86K
Nov 3, 2026$5.16$5.39$5.16$5.19489.36K
Nov 2, 2026$5.10$5.22$5.04$5.15622.51K
Oct 30, 2026$5.18$5.29$4.96$5.10567.19K
Oct 29, 2026$5.45$5.51$5.2021$5.28619.57K
Oct 28, 2026$5.40$5.40$5.09$5.37573.97K
Oct 27, 2026$5.32$5.49$5.22$5.39955.24K
Oct 26, 2026$5.42$5.51$5.13$5.30667.49K
Oct 23, 2026$5.09$5.20$5.01$5.17754.75K
Oct 22, 2026$5.37$5.46$5.05$5.13905.74K
Oct 21, 2026$5.85$6.04$5.395$5.43875K
Oct 20, 2026$5.73$6.04$5.545$5.78752.39K
Oct 19, 2026$6.10$6.22$5.61$5.731.34M

Latest TNXP news

The latest Smart Investors Daily articles mentioning TNXP.

Stock researchCompany · Overview

TNXP research

Overview

Company profile and research snapshot.

Company profile

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TNXP recent ratings
DateFirmRatingTarget
Oct 26, 2026Canaccord GenuityBuy—
Jun 25, 2026Raymond JamesStrong Buy—
May 4, 2026TD CowenBuy—
Mar 20, 2025Noble Capital MarketsOutperform—
Jul 22, 2024Alliance Global PartnersBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Tonix Pharmaceuticals (TNXP) Stock Fair Value Falls As Analysts Weigh Tonmya And Funding Risk

The latest update for Tonix Pharmaceuticals Holding shows the illustrative fair value estimate shifting from US$42.40 to US$34.00, which means analysts are now modeling less upside for the stock than before. This change aligns with recent Street research that combines optimism around Tonmya and the broader pipeline with concerns about ongoing financing needs and execution on commercial plans. As you read on, you will see how these moving pieces fit together and how to keep track of the...

Yahoo · Nov 11, 2026

Tonix Pharmaceuticals’ TONMYA Sales Jump 37% as Insurance Coverage Expands

Tonix Pharmaceuticals (NASDAQ:TNXP) said sales of its fibromyalgia treatment TONMYA rose 37% in the third quarter, as the company expanded insurance access and increased its sales force. Chief Executive Seth Lederman told biopharma analyst Vamil Divan at the Guggenheim Healthcare Innovation Confere

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By